following an abbreviated submission:
beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium (Trimbow®) is accepted for use within NHSScotland.
Indication under review: maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.
Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium (Trimbow®) offers an additional treatment choice of medium dose inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) in a single inhaler. SMC has previously accepted an alternative LAMA as an add-on treatment to ICS and LABA in asthma.
Download detailed advice733KB (PDF)
Medicine details
- Medicine name:
- beclometasone dipropionate/formoterol fumarate dehydrate/glycopyrronium bromide (Trimbow)
- SMC ID:
- SMC2335
- Indication:
Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.
- Pharmaceutical company
- Chiesi Limited
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 March 2021